Novartis Sees Opportunities In Financial Crisis, CEO Tells Tokyo Business Group
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Novartis CEO Daniel Vasella told an audience in Tokyo last week that "the current [global financial] situation creates opportunities because [Novartis has] a very solid free cash flow and most [Novartis] companies have a solid free cash flow and are not in a highly indebted environment.
You may also be interested in...
Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus
Product launches will follow listing by Japan’s Central Social Insurance Medical Council.
Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus
Product launches will follow listing by Japan’s Central Social Insurance Medical Council.
Novartis Japan Looks To Capitalize On Drug Approval Spurt, Submits NDA For Everolimus
Novartis Japanese subsidiary Novartis Pharma KK announced Jan. 21 four new drug approvals from Japan's Ministry of Health, Labor and Welfare. The new drugs are approved to treat asthma, hypertension, cancer and age-related macular degeneration